They also demonstrated that breast cancer cell proliferation could be reduced by knock-downing CTSD-IFITM10 mRNA expression via targeting its fusion junction region with custom small interfering RNAs, suggesting that the conjoined genes might, in the future, be a diagnostic biomarker and therapeutic target for treating a breast cancer subtype harboring those fusion biomarkers. This evidence concerns the gene IFITM10 and breast carcinoma.